Beijing, China

Zhengming Du

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Zhengming Du

Introduction

Zhengming Du is a notable inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative drug formulations. His work focuses on improving drug delivery systems to enhance patient outcomes.

Latest Patents

Zhengming Du holds a patent for an oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and its preparation method. The patent describes an oral solid tablet that includes (S)-7-[4-(1-acryloylpiperidine)]-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide. This formulation exhibits excellent drug release characteristics, ensuring easy administration and quick, efficient release. The preparation process is straightforward, requiring no special equipment, which contributes to formulation stability and facilitates transportation and storage. This innovation is particularly suitable for large-scale production.

Career Highlights

Zhengming Du is currently associated with Beigene Switzerland GmbH, where he continues to advance his research and development efforts. His work has been instrumental in creating effective pharmaceutical solutions that address critical health challenges.

Collaborations

Zhengming has collaborated with notable colleagues, including Gang Qiu and Yiwei Shen, to further enhance the impact of his innovations in the pharmaceutical industry.

Conclusion

Zhengming Du's contributions to drug formulation and delivery systems exemplify the importance of innovation in healthcare. His patent for an oral solid tablet represents a significant advancement in the field, showcasing his commitment to improving patient care through effective pharmaceutical solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…